“Off-the-Shelf” Allogeneic CAR Cell Therapy—Neglected HvG Effect

Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020;4(10):2325–38. https://doi.org/10.1182/bloodadvances.2020001466.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–44. https://doi.org/10.1056/NEJMoa1707447.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang M, Jin X, Sun R, Xiong X, Wang J, Xie D, et al. Optimization of metabolism to improve efficacy during CAR-T cell manufacturing. J Transl Med. 2021;19(1):499. https://doi.org/10.1186/s12967-021-03165-x.

Article  PubMed  PubMed Central  Google Scholar 

Khurana A, Lin Y. Allogeneic Chimeric antigen receptor therapy in lymphoma. Curr Treat Options Oncol. 2022;23(2):171–87. https://doi.org/10.1007/s11864-021-00920-6.

Article  PubMed  PubMed Central  Google Scholar 

Poehlein CH, Haley DP, Walker EB, Fox BA. Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunol. 2009;39(11):3121–33. https://doi.org/10.1002/eji.200939453.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499–503. https://doi.org/10.1038/s41591-018-0201-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discovery. 2020;19(3):185–99. https://doi.org/10.1038/s41573-019-0051-2. Summarizing the differences between the autologous and allogeneic CAR-T cells, illustrating the potential strategies to improve the GVHD effect and increase the persistence of allogenic CAR-T cells. This review is very comprehensive about allogenic CAR-cell therapy.

Ruella M, Kenderian SS. Next-generation chimeric antigen receptor T-cell therapy: going off the shelf. BioDrugs : Clin Immunotherapeutics, Biopharmaceuticals Gene Ther. 2017;31(6):473–81. https://doi.org/10.1007/s40259-017-0247-0.

Article  CAS  Google Scholar 

Torikai H, Cooper LJ. Translational implications for off-the-shelf immune cells expressing chimeric antigen receptors. Mol Ther: J Am Soc Gene Ther. 2016;24(7):1178–86. https://doi.org/10.1038/mt.2016.106.

Article  CAS  Google Scholar 

• Zhang Y, Li P, Fang H, Wang G, Zeng X. Paving the way towards universal chimeric antigen receptor therapy in cancer treatment: current landscape and progress. Front Immunol. 2020;11:604915. https://doi.org/10.3389/fimmu.2020.604915. Summarizing the methods for reducing GVHD and HvG effects in allogenic CAR-T cells.

June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med. 2015;7(280):280ps7. https://doi.org/10.1126/scitranslmed.aaa3643.

Article  CAS  PubMed  Google Scholar 

Patel K, Bachanova V, Goodman AM, Pagel JM, Griffis K, Anderson M, et al. Phase I Study of FT516, an off-the-shelf iPSC-derived NK cell therapy, in combination with rituximab in patients with relapsed/refractory B-cell lymphoma. Blood. 2021;138(Supplement 1):3873. https://doi.org/10.1182/blood-2021-151520.

Article  Google Scholar 

Cichocki F, Goodridge JP, Bjordahl R, Gaidarova S, Mahmood S, Abujarour R, et al. Off-the-shelf, multiplexed-engineered iPSC-derived NK cells mediate potent multi-antigen targeting of B-cell malignancies with reduced cytotoxicity against healthy B cells. Blood. 2021;138(Supplement 1):407. https://doi.org/10.1182/blood-2021-148654.

Article  Google Scholar 

Bachanova V, Ghobadi A, Patel K, Park JH, Flinn IW, Shah P, et al. Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphoma. Blood. 2021;138(Supplement 1):823. https://doi.org/10.1182/blood-2021-151185.

Article  Google Scholar 

Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in universal CAR-T cell therapy. Front Immunol. 2021;12:744823. https://doi.org/10.3389/fimmu.2021.744823.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Dhakal B, Chhabra S, Savani BN, Hamadani M. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. Br J Haematol. 2022;197(1):28–40. https://doi.org/10.1111/bjh.17904. Summerizing some results of partial clinical trials of allogenic CAR-T cell therapy. Explaining the reasons for GVHD and HvG effects of allogenic CAR-T cells and briefly summarizing some solutions.

McCreedy BJ, Senyukov VV, Nguyen KT. Off the shelf T cell therapies for hematologic malignancies. Best Pract Res Clin Haematol. 2018;31(2):166–75. https://doi.org/10.1016/j.beha.2018.03.001.

Article  PubMed  Google Scholar 

Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018;11(1):132. https://doi.org/10.1186/s13045-018-0677-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao XY, Xu ZL, Mo XD, Chen YH, Lv M, Cheng YF, et al. Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia. 2022;36(1):267–70. https://doi.org/10.1038/s41375-021-01351-w.

Article  CAS  PubMed  Google Scholar 

Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, et al. Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nature Biomed Eng. 2021;5(5):429–40. https://doi.org/10.1038/s41551-021-00730-z.

Article  CAS  Google Scholar 

Furukawa Y, Hamano Y, Shirane S, Kinoshita S, Azusawa Y, Ando J, et al. Advances in allogeneic cancer cell therapy and future perspectives on "off-the-shelf" T cell therapy using iPSC technology and gene editing. Cells. 2022;11(2). https://doi.org/10.3390/cells11020269

Li YR, Zhou Y, Kim YJ, Zhu Y, Ma F, Yu J, et al. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell Rep Med. 2021;2(11):100449. https://doi.org/10.1016/j.xcrm.2021.100449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wallet MA, Nishimura T, Del Casale C, Lebid A, Salantes B, Santostefano K, et al. Induced pluripotent stem cell-derived gamma delta CAR-T cells for cancer immunotherapy. Blood. 2021;138(Supplement 1):2771. https://doi.org/10.1182/blood-2021-149095.

Article  Google Scholar 

Byrne SM, Mali P, Church GM. Genome editing in human stem cells. Methods Enzymol. 2014;546:119–38. https://doi.org/10.1016/b978-0-12-801185-0.00006-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Stegen SJC, Lindenbergh PL, Petrovic RM, Xie H, Diop MP, Alexeeva V, et al. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nat Biomed Eng. 2022. https://doi.org/10.1038/s41551-022-00915-0.

Article  PubMed  Google Scholar 

Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520–31. https://doi.org/10.1038/leu.2017.226.

Article  CAS  PubMed  Google Scholar 

Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73. https://doi.org/10.1186/s13045-021-01083-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197–223. https://doi.org/10.1146/annurev.immunol.19.1.197.

Article  CAS  PubMed  Google Scholar 

Guven H, Konstantinidis KV, Alici E, Aints A, Abedi-Valugerdi M, Christensson B, et al. Efficient gene transfer into primary human natural killer cells by retroviral transduction. Exp Hematol. 2005;33(11):1320–8. https://doi.org/10.1016/j.exphem.2005.07.006.

Article  CAS  PubMed  Google Scholar 

Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res: CR. 2022;41(1):119. https://doi.org/10.1186/s13046-022-02327-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res: an Off J Am Assoc Cancer Res. 2014;20(22):5708–19. https://doi.org/10.1158/1078-0432.Ccr-13-3451.

Article  CAS  Google Scholar 

Kalyan S, Kabelitz D. Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic. Cell Mol Immunol. 2013;10(1):21–9. https://doi.org/10.1038/cmi.2012.44.

Article  CAS  PubMed  Google Scholar 

Born WK, Kemal Aydintug M, O’Brien RL. Diversity of γδ T-cell antigens. Cell Mol Immunol. 2013;10(1):13–20. https://doi.org/10.1038/cmi.2012.45.

Article  CAS  PubMed  Google Scholar 

Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science (New York, NY). 2005;309(5732):264–8. https://doi.org/10.1126/science.1110267.

Article  CAS  Google Scholar 

Nishimoto KP, Barca T, Azameera A, Makkouk A, Romero JM, Bai L, et al. Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models. Clin Transl Immunol. 2022;11(2):e1373. https://doi.org/10.1002/cti2.1373.

Article  CAS  Google Scholar 

Caldwell KJ, Gottschalk S, Talleur AC. Allogeneic CAR cell therapy-more than a pipe dream. Front Immunol. 2020;11:618427. https://doi.org/10.3389/fimmu.2020.618427.

Article  CAS  PubMed  Google Scholar 

• Mo F, Mamonkin M, Brenner MK, Heslop HE. Taking T-cell oncotherapy off-the-shelf. Trends Immunol. 2021;42(3):261–72. https://doi.org/10.1016/j.it.2021.01.004. Summarizing the methods for reducing GVHD and HvG effects in allogenic CAR-T cells briefly.

Quach DH, Ramos CA, Lulla PD, Sharma S, Ganesh HR, Hadidi YF, et al. Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr virus-specific T cells in patients with CD30-positive lymphoma. Blood. 2021;138(Supplement 1):1763. https://doi.org/10.1182/blood-2021-153421.

Article  Google Scholar 

Quach DH, Ramos CA, Lulla PD, Sharma S, Ganesh HR, Nouraee N, et al. CD30.CAR-modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma. Blood. 2022;140(Supplement 1):412–4. https://doi.org/10.1182/blood-2022-160244.

留言 (0)

沒有登入
gif